In this same study, GRAIL was found to be increased and IL-21R decreased in PBMCs isolated from patients with lymphoma when compared with healthy donors, suggesting that targeting GRAIL clinically (most likely via a small molecule inhibitor) may be especially useful in the treatment of lymphoma. Here, IL21R is linked to lymphoma.